Buy Rating for Palisade Bio: Promising Phase 1a Trial Results and Strategic Focus on Unmet Needs in Crohn’s Disease

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Palisade Bio (PALI – Research Report), with a price target of $2.00.

Naz Rahman has given his Buy rating due to a combination of factors including the promising results from Palisade Bio’s Phase 1a trial for PALI-2108. The trial demonstrated that PALI-2108 is safe and well-tolerated, with a favorable pharmacokinetic profile that suggests potential for once-daily dosing. The drug’s extended release and minimal systemic adverse effects support its chronic use, which is a positive indicator for its future development.
Naz Rahman also notes the strategic focus of Palisade Bio on fibrostenotic Crohn’s disease, a market with significant unmet needs and limited competition. The company’s plan to advance PALI-2108 into further clinical trials, including a Phase 1b study and discussions with the FDA, reflects a prudent development strategy. This strategic direction, coupled with the drug’s potency and targeted delivery, underpins the Buy rating, as it positions Palisade Bio to address a niche market effectively.

PALI’s price has also changed dramatically for the past six months – from $2.460 to $0.687, which is a -72.07% drop .